相关实验视频

Updated: Jun 22, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

一种临床神经学方法对患有腺氨酸脱氨酶缺乏症的儿童

Paula Ivarola¹, Luciano Urdinez², Matias Oleastro²

¹Department of Neurology, Hospital Nacional de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina.

Pediatric neurology

|July 3, 2024

概括

氨酸脱氨酶缺乏导致严重的综合免疫缺陷,经常出现神经问题,如发育迟缓和发作. 早期的神经学评估对受影响的儿童至关重要,因为免疫治疗不能逆转大脑损伤.

科学领域:

儿科神经学儿科神经学
免疫学免疫学免疫学
生物化学生物化学

背景情况:

严重的综合免疫缺陷 (SCID) 由于腺氨酶酶酶 (ADA) 缺乏症是一种罕见的遗传疾病.
缺乏ADA导致组织中有毒基质的积累,特别是大脑,导致神经症状.
神经学表现包括发作,发育障碍,低血压和神经神经传感器听力损失,这些症状并未通过血造干细胞移植逆转.

研究的目的:

为了描述患有ADA缺乏症SCID的儿童的神经并发症.
通过使用电生理学,放射学和神经认知学研究,提出一个高效的神经评估协议.

主要方法:

进行了一项描述性,观察性研究 (追溯和前性).
在1996年至2021年期间,被证实患有ADA缺乏症SCID的患者被评估.
神经学评估包括临床评估,神经成像和电生理学研究.

主要成果:

分析了10名患有ADA缺乏症SCID的患者.
所有患者都表现出神经发育延迟;常见的发现包括低血压 (6/10),神经感官听力损失 (4/10) 和语言延迟 (3/10).
神经成像显示大脑化 (4/10) 和下关节空间扩大 (2/10);两名患者出现了.

结论:

神经参与和神经成像异常在儿科ADA缺乏性SCID中很常见.
中枢神经系统基质积累是可能的原因,但必须排除慢性感染.
儿童神经科医生应该成为这些患者多学科护理的组成部分.

关键词:

亚丁氨酸 (Adenosine) 是一种氨基酸.亚丁氨酸脱氨酶的使用大脑的化.认知障碍认知障碍是一种认知障碍.发作在发作.感官神经神经听力损失是什么

更多相关视频

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy

Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy

Published on: January 11, 2016

相关概念视频

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...